Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTX-315 plus adoptive T-cell therapy in advanced or metastatic soft tissue sarcoma
2017-002877-20Phase 2Completed
- Sponsor
- Lytix Biopharma
- Start
- Feb 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxotemitide, GC101 TIL + pembrolizumab, cyclophosphamide, fludarabine and aldesleukin in soft tissue sarcoma (STS), sponsored by Lytix Biopharma. Primary endpoint: Change in total T-cell level in tumor tissues. Started Feb 2018; status: completed.
02
Drugs
ruxotemitideGC101 TIL + pembrolizumabcyclophosphamidefludarabinealdesleukin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2017-002877-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002877-20.